Status:
COMPLETED
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
Lead Sponsor:
Novartis
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
2-17 years
Phase:
PHASE4
Brief Summary
Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These...
Eligibility Criteria
Inclusion
- Severe atopic dermatitis
- 5% of total body surface area (TBSA) affected
Exclusion
- Concurrent skin diseases (infections)
- Immunocompromised
- Recently received phototherapy or systemic therapy
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00121381
Start Date
May 1 2005
End Date
January 1 2007
Last Update
January 15 2008
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Care Medical Group, Inc.
Huntington Beach, California, United States, 92647
2
Children's Hospital -San Diego
San Diego, California, United States, 92123
3
National Jewish Medical and Research Center
Denver, Colorado, United States, 80206
4
Dermatology Associates and Research
Coral Gables, Florida, United States, 33134